• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 6, 2017

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Blocking poly (ADP-ribose) polymerase (PARP) will selectively kill tumor cells with some types of DNA repair deficiencies, a vulnerability known as synthetic lethality. Read More

Reata data do: CARDINAL sings in Alport disease

Presenting during the late-breaking clinical trial posters at Kidney Week in New Orleans, Reata Pharmaceuticals Inc. did not disappoint with primary 12-week data from the phase II portion of its CARDINAL trial of bardoxolone methyl (bard) to treat chronic kidney disease (CKD) caused by Alport syndrome. Read More

Redx ready to focus on pipeline after emerging from administration

LONDON – Shares in Redx Pharma plc will start trading again on Monday at midday, five months after it was forced into administration after failing to repay a £3.5 million (US$4.6 million) loan from Liverpool City Council. Read More

Appointments and advancements

TCR2 Therapeutics Inc., of Cambridge, Mass., named Andrew Cornforth vice president of process development; Daniel Getts vice president of research; and Alfonso Quintás chief medical officer. Read More

In the clinic

Alexion Pharmaceuticals Inc., of New Haven, Conn., reported new interim data from a trial testing Kanuma (sebelipase alfa) in patients with rapidly progressive lysosomal acid lipase deficiency at the NASPGHAN Annual Meeting in Las Vegas. Of the 10 infants treated with Kanuma, nine survived beyond 1 year of age, compared to a median age of death of 3.7 months with mortality by 1 year of nearly 100 percent for historically untreated infants. Read More

Other news to note

Valeant Pharmaceuticals International Inc., of Laval, Quebec, said subsidiary Bausch & Lomb and Sophia Antipolis, France-based Nicox SA gained FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution, 0.024 percent) for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Bausch & Lomb in-licensed the program from Nicox in 2010. Read More

Financings

Cipher Pharmaceuticals Inc., of Mississauga, Ontario, said it entered a new three-year, $20 million senior secured term credit facility with Canadian Imperial Bank of Commerce. Read More

Startups dominating novel approaches to seemingly intractable medical problems

PALM SPRINGS, Calif. – At a health care conference devoted to big ideas that could shift the future of care, med-tech startups were front and center. They brought forth a vision of a range of innovative technologies: using gene-editing CRISPR for at-home diagnostics, machine learning for more accurate imaging interpretation, bioelectronics for chronic diseases, virtual reality for surgical training, and liquid biopsy to detect asymptomatic, age-related diseases. Read More

Chi-Med advancing fruquintinib into phase III trial in gastric cancer

HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) said the phase III trial of its oral vascular endothelial growth factor (VEGF) inhibitor fruquintinib has begun. Named FRUTIGA, the randomized, double-blind, placebo-controlled, multicenter study is to test fruquintinib's efficacy and safety in combination with chemotherapy paclitaxel for the treatment of advanced gastric cancer, or gastroesophageal junction adenocarcinoma, in China. Read More

Ace of BACE? Signs seen that mechanism may block AD before symptoms arise

In developing aducanumab, one of the more promising therapies for Alzheimer's disease (AD), Neurimmune Therapeutics AG took a creative approach – one that caught the eye of Biogen Inc. "Aducanumab actually comes from a human individual, someone who was in his or her late 90s or early 100s," Ajay Verma, previously with Cambridge, Mass.-based Biogen, told BioWorld. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Vertex Pharmaceuticals discovers new PKD1 correctors

    BioWorld Science
    Vertex Pharmaceuticals Inc. has described polycystin-1 (PKD1) (mutant) correctors reported to be useful for the treatment of autosomal dominant polycystic kidney...
  • Ozempic pen and packaging

    EMA warns Ozempic linked to ‘very rare’ side effect

    BioWorld
    The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe